SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Janssen Therapeutics Release: FDA Approves Prescribing Information Update for EDURANT® (Rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients